{"success":true,"data":{"pressRelease":{"id":"122173","rtpr_id":"nGNXbQlJ9H","ticker":"EIKN","exchange":"NASDAQ","all_tickers":["EIKN"],"title":"Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald","author":"Globe Newswire","published_at":"2026-08-18T20:15:00.139Z","article_body":"MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc.\n(Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company\ndedicated to developing innovative medicines to address serious unmet medical\nneeds, today announced that its Chairman and Chief Executive Officer, Roger M.\nPerlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event\non Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and\nfeaturing Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and\nphysician scientist from the University of Texas MD Anderson Cancer Center.\n\nDr. Timothy A. Yap currently serves as Vice President and Head of Clinical\nDevelopment in the Therapeutics Discovery Division at the University of Texas\nMD Anderson Cancer Center, and is a Professor in the Department for\nInvestigational Cancer Therapeutics (Phase I Program) and in the Department of\nThoracic/Head and Neck Medical Oncology. Dr. Yap is and/or has been Principal\nInvestigator for multiple clinical trials and translational studies evaluating\nnovel strategies for targeting the DNA damage response in cancer and is an\nexpert in the use of PARP inhibitors in oncology. Dr. Yap receives\ncompensation as an advisor to Eikon, and this financial relationship has been\ndisclosed to UT MD Anderson’s Conflict of Interest Committee in accordance\nwith its institutional policy. Dr. Yap will discuss the current therapeutic\nlandscape of PARP inhibition in breast, ovarian, prostate and pancreatic\ncancer, including usage of approved agents, therapeutic outcomes and\nlimitations of currently available agents targeting PARP and parylation in\noncology.\n\nThe event will be hosted by Imogen Mansfield at Cantor Fitzgerald. To access\nthe archived webcast, please visit\nhttp://investors.eikontx.com/news-events/events. A replay will be available on\nthe Eikon website for 30 days following the event.\n\nAbout Eikon Therapeutics\nEikon is a late-stage clinical biopharmaceutical company dedicated to building\na global, fully-integrated organization developing innovative medicines to\naddress serious unmet medical needs. Eikon’s initial focus is oncology,\nwhere it is advancing a pipeline of drug candidates targeting areas of high\nunmet need that could eventually become critical medicines for the treatment\nof various cancers. Eikon deploys its technology platform, including its\nproprietary single molecule tracking system, to develop internally-derived\nnovel therapies, while also leveraging the deep expertise of its management\nteam to in-license promising assets. Eikon’s vision is to become a\ngenerational leader, by purposefully integrating traditional biology research\nwith advanced engineering to develop better medicines faster. For more\ninformation, visit www.eikontx.com.\n\nForward-Looking/Safe Harbor Statements\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995. All statements in this press release that are not historical\nfacts are hereby identified as forward-looking statements for this purpose.\nThese statements may be identified by words such as “aims,”\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “forecasts,” “goal,” “intends,” “may,”\n“plans,” “possible,” “potential,” “seeks,” “will” and\nvariations of these words or similar expressions that are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. Forward-looking statements in this press release include,\nbut are not limited to, statements regarding: the therapeutic potential,\nsafety, and efficacy of Eikon’s product candidates; the timing for\nanticipated data readouts; expected milestones and business objectives for\n2026 and beyond; and other statements regarding Eikon’s future operations,\nfinancial performance, financial position, prospects, objectives, strategies\nand other future events.\n\nThese forward-looking statements are based upon management’s current\nexpectations and assumptions, and are subject to a number of risks,\nuncertainties and other factors that could cause actual results and events to\ndiffer materially and adversely from those indicated by such forward-looking\nstatements including, among others: our limited operating history; our\nsignificant net losses incurred since inception and the likelihood of\nincurring additional losses for the foreseeable future; our need for\nsubstantial additional funding; the early stage of development of many of our\nproduct candidates and the possibility that our product candidates may fail in\ndevelopment; our dependence on the success of our current product candidates;\nour ability to leverage our technology platform to enable more informed drug\nresearch and development; legal and regulatory risks; intellectual\nproperty-related risks; and those risks, uncertainties and other factors\ndiscussed under the caption “Risk Factors” and elsewhere in Eikon’s\nQuarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with\nthe Securities and Exchange Commission (“SEC”) on August 13, 2026, and in\nother public filings with the SEC in the future.\n\nAs a result, you should not place undue reliance on any forward-looking\nstatements. The forward-looking statements made in this press release speak\nonly as of the date of this press release, and Eikon undertakes no obligation\nto update such forward-looking statements, whether as a result of new\ninformation, future developments or otherwise, except as required by law.\n\nContacts:\n\nInvestors\nAlfred “Freddie” Bowie, Ph.D., CFO\nir@eikontx.com\n\nMedia\nColin Sanford\ncolin@bioscribe.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbQlJ9H","title":"Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald","author":"Globe Newswire","ticker":"EIKN","created":"2026-08-18T20:15:00.139Z","tickers":["EIKN"],"exchange":"NASDAQ","article_body":"MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc.\n(Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company\ndedicated to developing innovative medicines to address serious unmet medical\nneeds, today announced that its Chairman and Chief Executive Officer, Roger M.\nPerlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event\non Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and\nfeaturing Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and\nphysician scientist from the University of Texas MD Anderson Cancer Center.\n\nDr. Timothy A. Yap currently serves as Vice President and Head of Clinical\nDevelopment in the Therapeutics Discovery Division at the University of Texas\nMD Anderson Cancer Center, and is a Professor in the Department for\nInvestigational Cancer Therapeutics (Phase I Program) and in the Department of\nThoracic/Head and Neck Medical Oncology. Dr. Yap is and/or has been Principal\nInvestigator for multiple clinical trials and translational studies evaluating\nnovel strategies for targeting the DNA damage response in cancer and is an\nexpert in the use of PARP inhibitors in oncology. Dr. Yap receives\ncompensation as an advisor to Eikon, and this financial relationship has been\ndisclosed to UT MD Anderson’s Conflict of Interest Committee in accordance\nwith its institutional policy. Dr. Yap will discuss the current therapeutic\nlandscape of PARP inhibition in breast, ovarian, prostate and pancreatic\ncancer, including usage of approved agents, therapeutic outcomes and\nlimitations of currently available agents targeting PARP and parylation in\noncology.\n\nThe event will be hosted by Imogen Mansfield at Cantor Fitzgerald. To access\nthe archived webcast, please visit\nhttp://investors.eikontx.com/news-events/events. A replay will be available on\nthe Eikon website for 30 days following the event.\n\nAbout Eikon Therapeutics\nEikon is a late-stage clinical biopharmaceutical company dedicated to building\na global, fully-integrated organization developing innovative medicines to\naddress serious unmet medical needs. Eikon’s initial focus is oncology,\nwhere it is advancing a pipeline of drug candidates targeting areas of high\nunmet need that could eventually become critical medicines for the treatment\nof various cancers. Eikon deploys its technology platform, including its\nproprietary single molecule tracking system, to develop internally-derived\nnovel therapies, while also leveraging the deep expertise of its management\nteam to in-license promising assets. Eikon’s vision is to become a\ngenerational leader, by purposefully integrating traditional biology research\nwith advanced engineering to develop better medicines faster. For more\ninformation, visit www.eikontx.com.\n\nForward-Looking/Safe Harbor Statements\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995. All statements in this press release that are not historical\nfacts are hereby identified as forward-looking statements for this purpose.\nThese statements may be identified by words such as “aims,”\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “forecasts,” “goal,” “intends,” “may,”\n“plans,” “possible,” “potential,” “seeks,” “will” and\nvariations of these words or similar expressions that are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. Forward-looking statements in this press release include,\nbut are not limited to, statements regarding: the therapeutic potential,\nsafety, and efficacy of Eikon’s product candidates; the timing for\nanticipated data readouts; expected milestones and business objectives for\n2026 and beyond; and other statements regarding Eikon’s future operations,\nfinancial performance, financial position, prospects, objectives, strategies\nand other future events.\n\nThese forward-looking statements are based upon management’s current\nexpectations and assumptions, and are subject to a number of risks,\nuncertainties and other factors that could cause actual results and events to\ndiffer materially and adversely from those indicated by such forward-looking\nstatements including, among others: our limited operating history; our\nsignificant net losses incurred since inception and the likelihood of\nincurring additional losses for the foreseeable future; our need for\nsubstantial additional funding; the early stage of development of many of our\nproduct candidates and the possibility that our product candidates may fail in\ndevelopment; our dependence on the success of our current product candidates;\nour ability to leverage our technology platform to enable more informed drug\nresearch and development; legal and regulatory risks; intellectual\nproperty-related risks; and those risks, uncertainties and other factors\ndiscussed under the caption “Risk Factors” and elsewhere in Eikon’s\nQuarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with\nthe Securities and Exchange Commission (“SEC”) on August 13, 2026, and in\nother public filings with the SEC in the future.\n\nAs a result, you should not place undue reliance on any forward-looking\nstatements. The forward-looking statements made in this press release speak\nonly as of the date of this press release, and Eikon undertakes no obligation\nto update such forward-looking statements, whether as a result of new\ninformation, future developments or otherwise, except as required by law.\n\nContacts:\n\nInvestors\nAlfred “Freddie” Bowie, Ph.D., CFO\nir@eikontx.com\n\nMedia\nColin Sanford\ncolin@bioscribe.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-18T20:15:00.204633993Z","server_sent_at_ms":1787084100204},"received_at":"2026-08-18T20:15:00.287Z","source_url":"https://www.globenewswire.com/news-release/2026/08/18/3347241/0/en/eikon-therapeutics-to-participate-in-kol-event-on-therapeutic-use-of-parp-inhibitors-in-oncology-hosted-by-cantor-fitzgerald.html"},"analysis":{"id":"111157","press_release_id":"122173","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Eikon Therapeutics CEO Roger M. Perlmutter will participate in a Key Opinion Leader event hosted by Cantor Fitzgerald on August 20, 2026.\n\nThe event features Dr. Timothy A. Yap of MD Anderson Cancer Center, an expert in PARP inhibitors and a compensated advisor to Eikon, discussing the therapeutic landscape in breast, ovarian, prostate, and pancreatic cancer.\n\nAn archived webcast will be available on the Eikon investor website for 30 days following the event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-material marketing event participation."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Roger M. Perlmutter","role":"Chairman and CEO"},{"name":"Timothy A. Yap","role":"Medical Oncologist, Professor, Advisor"},{"name":"Imogen Mansfield","role":"Host at Cantor Fitzgerald"},{"name":"Alfred “Freddie” Bowie","role":"CFO"}],"products":[],"companies":[{"name":"Eikon Therapeutics, Inc.","ticker":"EIKN"},{"name":"Cantor Fitzgerald","relationship":"host"},{"name":"University of Texas MD Anderson Cancer Center","relationship":"institutional affiliation"},{"name":"Bioscribe","relationship":"media contact"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of a KOL (Key Opinion Leader) event participation hosted by an investment bank. No clinical data, financial results, or regulatory milestones disclosed."},"tickerRelevance":{"others":[],"primary":"EIKN"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"kol_event_participation","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Eikon Therapeutics CEO Roger M. Perlmutter will participate in a Key Opinion Leader event hosted by Cantor Fitzgerald on August 20, 2026.\n\nThe event features Dr. Timothy A. Yap of MD Anderson Cancer Center, an expert in PARP inhibitors and a compensated advisor to Eikon, discussing the therapeutic landscape in breast, ovarian, prostate, and pancreatic cancer.\n\nAn archived webcast will be available on the Eikon investor website for 30 days following the event.","key_figures":null,"named_entities":{"people":[{"name":"Roger M. Perlmutter","role":"Chairman and CEO"},{"name":"Timothy A. Yap","role":"Medical Oncologist, Professor, Advisor"},{"name":"Imogen Mansfield","role":"Host at Cantor Fitzgerald"},{"name":"Alfred “Freddie” Bowie","role":"CFO"}],"products":[],"companies":[{"name":"Eikon Therapeutics, Inc.","ticker":"EIKN"},{"name":"Cantor Fitzgerald","relationship":"host"},{"name":"University of Texas MD Anderson Cancer Center","relationship":"institutional affiliation"},{"name":"Bioscribe","relationship":"media contact"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-18T20:34:52.794Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"kol_event_participation","sectorWeight":"biotech"}},"durationMs":194294,"modelName":"glm-4.7"}}